| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A quality alert and call for improved curation of public chemistry databases
|
Williams, Antony J.
|
|
2011
|
16 |
17-18 |
p. 747-750
4 p.
|
artikel
|
| 2 |
Contents
|
|
|
2011
|
16 |
17-18 |
p. i-
1 p.
|
artikel
|
| 3 |
Contents
|
|
|
2011
|
16 |
17-18 |
p. iii-
1 p.
|
artikel
|
| 4 |
Drug discovery in the next decade: innovation needed ASAP
|
Bennani, Youssef L.
|
|
2011
|
16 |
17-18 |
p. 779-792
14 p.
|
artikel
|
| 5 |
Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity
|
Young, Robert J.
|
|
2011
|
16 |
17-18 |
p. 822-830
9 p.
|
artikel
|
| 6 |
How well do medicinal chemists learn from experience?
|
Cheshire, David R.
|
|
2011
|
16 |
17-18 |
p. 817-821
5 p.
|
artikel
|
| 7 |
In silico SNP analysis and bioinformatics tools: a review of the state of the art to aid drug discovery
|
Mah, James T.L.
|
|
2011
|
16 |
17-18 |
p. 800-809
10 p.
|
artikel
|
| 8 |
Is informed consent necessary for randomized Phase IV ‘observational’ drug studies?
|
Bernabe, Rosemarie D.C.
|
|
2011
|
16 |
17-18 |
p. 751-754
4 p.
|
artikel
|
| 9 |
Matrix metalloproteinases as drug targets in ischemia/reperfusion injury
|
Dejonckheere, Eline
|
|
2011
|
16 |
17-18 |
p. 762-778
17 p.
|
artikel
|
| 10 |
Novel advances in cytochrome P450 research
|
Singh, Deepika
|
|
2011
|
16 |
17-18 |
p. 793-799
7 p.
|
artikel
|
| 11 |
Redox-active nuisance screening compounds and their classification
|
Baell, Jonathan B.
|
|
2011
|
16 |
17-18 |
p. 840-841
2 p.
|
artikel
|
| 12 |
Structure-based drug design to augment hit discovery
|
Kalyaanamoorthy, Subha
|
|
2011
|
16 |
17-18 |
p. 831-839
9 p.
|
artikel
|
| 13 |
The challenge of developing robust drugs to overcome resistance
|
Anderson, Amy C.
|
|
2011
|
16 |
17-18 |
p. 755-761
7 p.
|
artikel
|
| 14 |
Truncated HER2: implications for HER2-targeted therapeutics
|
Zagozdzon, Radoslaw
|
|
2011
|
16 |
17-18 |
p. 810-816
7 p.
|
artikel
|
Tijdschrift beschrijving